Hims & Hers: A CEO Pay Storm and a Pill-Fueled Competitive Squeeze

Hims & Hers faces investor backlash over CEO's 272:1 pay ratio, board nomination, and rising competition from Amazon and Eli Lilly in the GLP-1 market.

The telemedicine provider Hims & Hers is navigating a volatile stretch where internal governance controversies and external market pressures are colliding. The stock has been whipsawed by two distinct forces in recent days: a shareholder backlash over executive compensation and the intensifying threat from Big Pharma and Big Tech in the weight-loss drug arena.

A Compensation Gap That Stung

A single disclosure in the company’s latest proxy statement sent shares tumbling more than 5% on Tuesday, marking the worst single-day performance in a month. The culprit was the eye-popping pay ratio between Chief Executive Andrew Dudum and the median employee. Dudum took home roughly $22.96 million in 2025, while the typical worker earned $84,402 — a ratio of 272 to 1.

Although Dudum’s total compensation actually declined about 7% from the prior year, the structure of the package remains heavily skewed toward equity. He received 306,406 restricted stock units and performance-based stock options that can convert into anywhere from 278,622 shares at the minimum threshold to as many as 1.39 million shares at maximum performance. The exercise price of $34.71 sits well above the current market price, leaving those options underwater for now.

The optics are complicated by the company’s governance structure. Hims & Hers qualifies as a “controlled company” on the New York Stock Exchange because Dudum controls roughly 87.7% of voting power through super-voting Class V shares. That means the advisory vote on compensation at the virtual annual meeting scheduled for June 11, 2026, will be purely symbolic — but the market’s reaction suggests investors are paying attention nonetheless.

A Boardroom Addition and a Market Under Siege

Amid the pay controversy, the company announced on April 28 that it is nominating Kofi Amoo-Gottfried, a former DoorDash marketing chief and longtime Meta executive, to join the board. The vote will take place at the June shareholder meeting. Amoo-Gottfried’s expertise in brand-building and digital customer engagement arrives at a critical moment, as Hims & Hers fights to differentiate itself in a rapidly crowding marketplace.

The competitive landscape is shifting fast. Amazon One Medical launched its GLP-1 care program on April 21, bundling primary care, Amazon Pharmacy, and virtual consultations into a single offering. For a specialized telehealth platform like Hims & Hers, that represents a direct threat to its subscription model.

Then came the FDA approval of Eli Lilly’s daily weight-loss pill Foundayo (orforglipron) on April 1 — only the second oral GLP-1 drug to reach the market after Novo Nordisk’s Wegovy tablet. Hims & Hers had leaned heavily into GLP-1 therapies, including Novo Nordisk products and its own compounded formulations. The more alternatives that become available directly through pharmacies or integrated platforms, the harder it becomes to retain patients in a telemedicine subscription.

Analyst Divergence and Heavy Short Interest

Wall Street remains deeply split on the stock. Of the 18 analysts covering Hims & Hers, the majority rate it a “Hold.” JPMorgan initiated coverage with an “Overweight” rating and a $35 price target, while Citigroup downgraded to “Neutral” with a target of just $24. That 11-dollar spread underscores the uncertainty surrounding the company’s trajectory.

The bearish camp is unusually active. Short interest stands at 36.4% of the float — a strikingly high level that signals many traders are betting on further declines. The stock closed at $26.33 on April 30, down 5.7% on the day, and is trading in a technical range with support at $25 and resistance at $27.75.

Growth as a Defense

The company’s defenders point to the numbers. Revenue surged 59% in 2025 to $2.35 billion, with subscribers exceeding 2.5 million. Adjusted EBITDA reached $318 million, and the company hit 94% of its revenue target and 98% of its EBITDA goal. Operating cash flow stood at $300 million, though free cash flow came in at just $57.4 million — a reminder of the heavy reinvestment required to sustain that growth.

Despite the recent selloff, the stock has still gained roughly 34% in April, putting it on track for a second consecutive monthly advance. That resilience suggests the market is weighing the competitive threats against the underlying momentum.

The Next Catalyst

All eyes now turn to the first-quarter earnings report due on May 11. In the prior quarter, revenue grew 28.4% to $617.8 million, and the full-year target remains $2.35 billion. Analysts expect pressure on both earnings per share and EBITDA as the company balances growth investments against profitability. How management frames that trade-off — and how it addresses the twin challenges of compensation optics and competitive encroachment — will likely determine whether the stock can hold its April gains or give them back in May.